Holds, funds and steers ophthalmic portfolio companies developing advanced medical devices, drugs, diagnostics and digital eye-care products from preclinical work through first sales. It intends to earn by bringing those eye products to market through the portfolio companies, licensing technology to strategic partners, and realising its stakes.
